Skip to main content

Weather alert

Due to winter storm Fern, our Patient Service Centers in affected areas may be closed. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational. For site-specific information, please use Find a location and enter your zip code.

Hide
Quest Diagnostics

RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals

RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals

Authors: Vooren EV, den Broeck FV, Mahieu Q, Geens E, Heetvelde MV, De Bruyne M, de Sompele SV, Uppal S, Poliakov E, Dhaenens CM, Gregory-Evans CY, Hoefsloot L, Gonzalez AI, Kohl S, Zuleger T, Demaret T; Dominant RPE65-p.(E519K) Consortium; Tuupanen S, Ruys J, Os LV, Platteau E, Jacob J, Vermeer S, Postelmans L, Dahan K, Maystadt I, Rasquin F, Thiadens AAHJ, Stephenson KAJ, Sheri N, Smirnov V, MacDonald IM, Gregory-Evans K, Redmond TM, De Zaeytijd J, Leroy BP, Bauwens M, De Baere E.

Citation: Res Sq [Preprint]. 2025 May 5:rs.3.rs-5849564. doi: 10.21203/rs.3.rs-5849564/v2

Disclaimer: One or more of the authors of this publication were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Specialties:  Genetics

Related content

Publication
Late-onset autosomal dominant macular degeneration caused by deletion of the CRX gene
Publication
Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases
Conference Presentation
Quantifying the potential of genetic sequencing for identification and treatment for patients with inherited retinal disease
Conference Presentation
Next-Generation Sequencing Panel Results for Inherited Retinal Dystrophy in a Large Pediatric Cohort
Conference Presentation
Small CNVs, noncoding, and mitochondrial variants are molecularly diagnostic for 4.7% of pediatric patients with inherited retinal disease
Conference Presentation
Diagnostic Contribution of Genes with Treatments or Interventional Clinical Trials in a Large Retinal Dystrophy Cohort
Publication
A genetic and clinical study of individuals with nonsyndromic retinopathy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.